Afimkibart, an Anti-TL1A Antibody, in Moderately-to-Severely Active Ulcerative Colitis: Insights from the Phase 2b TUSCANY-2 Trial
Posted inClinical Updates Gastroenterology Specialties

Afimkibart, an Anti-TL1A Antibody, in Moderately-to-Severely Active Ulcerative Colitis: Insights from the Phase 2b TUSCANY-2 Trial

The TUSCANY-2 phase 2b trial evaluated afimkibart, a novel anti-TL1A antibody, in moderately-to-severely active ulcerative colitis, demonstrating favorable safety and clinically meaningful remission rates using modified Mayo scores despite primary endpoint statistical thresholds not being met by total Mayo scores.
Comparative Efficacy of Low FODMAP Plus Traditional Dietary Advice, Low-Carbohydrate Diet, and Pharmacological Treatment in Moderate-to-Severe IBS: Insights from the CARIBS Trial
Posted inClinical Updates Family Medicine & Nutrition Gastroenterology news Specialties

Comparative Efficacy of Low FODMAP Plus Traditional Dietary Advice, Low-Carbohydrate Diet, and Pharmacological Treatment in Moderate-to-Severe IBS: Insights from the CARIBS Trial

The CARIBS trial shows that both low FODMAP plus traditional dietary advice and a low-carbohydrate diet outperform optimized pharmacologic treatment in reducing IBS symptom severity after 4 weeks, highlighting the importance of dietary interventions as first-line therapy.
Silymarin in Clinical Medicine: A Decade of Therapeutic Advances and Future Disease Targets
Posted inClinical Updates Family Medicine & Nutrition Gastroenterology news Specialties

Silymarin in Clinical Medicine: A Decade of Therapeutic Advances and Future Disease Targets

Comprehensive review of recent decade research on silymarin elucidates its antioxidant, anti-inflammatory, and hepatoprotective effects, highlighting promising clinical applications in metabolic diseases, neurodegeneration, liver disorders, and inflammatory conditions, with emerging potential in oncology and dermatology.
Butyrate-Producing Clostridium butyricum: A Direct Interactor with Colorectal Cancer Cells that Reverses Immune Suppression and Enhances Checkpoint Inhibitor Efficacy
Posted inClinical Updates Family Medicine & Nutrition Gastroenterology news Oncology Specialties

Butyrate-Producing Clostridium butyricum: A Direct Interactor with Colorectal Cancer Cells that Reverses Immune Suppression and Enhances Checkpoint Inhibitor Efficacy

Recent research uncovers that the probiotic Clostridium butyricum directly interacts with colorectal cancer cells to inhibit immune suppression via the secD-GRP78 axis, restoring CD8+ T cell antitumor function and enhancing PD-1 inhibitor therapy.
Antibiotic Exposure as a Major Risk Factor for Clostridioides difficile Infection: Evidence from a Large Israeli Cohort and Systematic Reviews
Posted inCritical Care Gastroenterology Specialties

Antibiotic Exposure as a Major Risk Factor for Clostridioides difficile Infection: Evidence from a Large Israeli Cohort and Systematic Reviews

Recent research confirms that antibiotic exposure doubles the risk of hospital-onset Clostridioides difficile infection (CDI), especially in non-carriers, underscoring the central role of antibiotic stewardship and the need for additional preventive strategies in asymptomatic carriers.
Endoscopic Ultrasound-Guided Gastroenterostomy Reduces Reintervention in Malignant Gastric Outlet Obstruction: Insights from the Multicentre DRA-GOO Trial
Posted inGastroenterology General Surgery news Specialties

Endoscopic Ultrasound-Guided Gastroenterostomy Reduces Reintervention in Malignant Gastric Outlet Obstruction: Insights from the Multicentre DRA-GOO Trial

A multicentre RCT demonstrated that endoscopic ultrasonography-guided gastroenterostomy (EUS-GE) significantly lowers 6-month reintervention rates and improves gastric outlet obstruction symptoms compared to duodenal stenting in unresectable malignant gastric outlet obstruction.